These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases. Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073 [TBL] [Abstract][Full Text] [Related]
5. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Gualco G; Weiss LM; Harrington WJ; Bacchi CE Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150 [TBL] [Abstract][Full Text] [Related]
6. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas. Vazquez I; Papaleo N; Garcia E; Salido M; Salar A; Hernandez S; Calvo X; Colomo L Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260556 [TBL] [Abstract][Full Text] [Related]
7. Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression. Valera A; Epistolio S; Colomo L; Riva A; Balagué O; Dlouhy I; Tzankov A; Bühler M; Haralambieva E; Campo E; Soldini D; Mazzucchelli L; Martin V Mod Pathol; 2016 Aug; 29(8):844-53. PubMed ID: 27125356 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas. Moore EM; Swerdlow SH; Gibson SE Am J Surg Pathol; 2018 Mar; 42(3):342-350. PubMed ID: 29309299 [TBL] [Abstract][Full Text] [Related]
9. A combination of LMO2 negative and CD38 positive is useful for the diagnosis of Burkitt lymphoma. Liu Y; Bian T; Zhang Y; Zheng Y; Zhang J; Zhou X; Xie J Diagn Pathol; 2019 Sep; 14(1):100. PubMed ID: 31484540 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of 'double-hit' and 'double-expression' lymphomas. Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842 [TBL] [Abstract][Full Text] [Related]
11. Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity. Bhavsar S; Liu YC; Gibson SE; Moore EM; Swerdlow SH Am J Surg Pathol; 2022 Jan; 46(1):71-82. PubMed ID: 34392269 [TBL] [Abstract][Full Text] [Related]
12. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis. Lynnhtun K; Renthawa J; Varikatt W Pathology; 2014 Apr; 46(3):211-5. PubMed ID: 24614699 [TBL] [Abstract][Full Text] [Related]
13. [Aggressive B-cell lymphomas of gastrointestinal tract: a clinicopathologic analysis of 54 cases]. Zhou J; Xia C; Shen Q; Yin H; Zhang X; Shi Q; Zhou X; Ma J Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):8-14. PubMed ID: 24713242 [TBL] [Abstract][Full Text] [Related]
14. High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas. Shams TM J Egypt Natl Canc Inst; 2011 Dec; 23(4):147-53. PubMed ID: 22776842 [TBL] [Abstract][Full Text] [Related]
15. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract. Chapman-Fredricks J; Younes SF; Fan YS; Sandoval-Sus JD; Natkunam Y; Lossos IS Appl Immunohistochem Mol Morphol; 2013 May; 21(3):200-4. PubMed ID: 22914613 [TBL] [Abstract][Full Text] [Related]
17. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713 [TBL] [Abstract][Full Text] [Related]
18. Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with Chapman J; Verdun RE; Lossos IS Leuk Lymphoma; 2021 Oct; 62(10):2547-2550. PubMed ID: 33988072 [No Abstract] [Full Text] [Related]
19. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma. Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389 [TBL] [Abstract][Full Text] [Related]
20. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]